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Abstract
Background Despite promising results, laser-assisted drug
delivery (LADD) is not yet considered as standard thera-
pies and published data rely mainly on laboratory tests,
animal experiments or cadaver skin.
Objectives This double-blind, prospective, randomized
clinical trial investigates the impact in topical application
of vitamin C and a cosmeceutical containing growth factors
(GFs) on periorbital wrinkles primarily treated with laser
skin resurfacing.
Material and Methods In total, 149 female patients with
periorbital wrinkles were consented and randomized into
two study groups, R-C (receiving vitamin C only) and
R-CGF (receiving vitamin C and a cosmeceutical con-
taining growth factors). The statistical analysis evaluated
the efficacy of each treatment regimen using software
readouts provided by a three-dimensional stereopho-
togrammetry system prior to treatment and three months
after the procedure. Results were compared to confirm if
there was a significant change in the skin roughness and the
average depth of the wrinkles between the two groups after
treatment.
Results There was a significant reduction in both skin
roughness and average depth of the wrinkles in the group
treated with vitamin C and growth factors (p\0.01) than
those treated with LADD followed by topical application
of vitamin C alone. There were no cutaneous reactions or
adverse systemic reactions observed in this study related to
LADD with vitamin C and GFs.
Conclusion Controlled laser application might have a great
potential to facilitate the absorption of exogenous macro-
molecules by the skin. Periorbital wrinkles were reduced in
both groups, but LADD using vitamin C and GFs provided
significantly better results.
Level of Evidence II This journal requires that authors
assign a level of evidence to each article. For a full
description of these Evidence-Based Medicine ratings,
please refer to the Table of Contents or the online
Instructions to Authors www.springer.com/00266.
Keywords Laser-assisted medication  Laser-assisted drug
delivery  Wrinkles  Growth factors  Vitamin C
Introduction
The senescence of human skin is characterized by the
action of physical and biochemical ageing processes within
a bi-layer comprised of a rigid superficial stratum corneum
(SC), lying on a deeper and less rigid dermis. This phe-
nomenon causes a comparative shrinkage of the more rigid
layer over the softer layer, and this leads to the classical
appearance of wrinkles. These skin depressions more fre-
quently occur in sun-exposed regions or areas that are
subject to repeated movements such as face, neck and
hands [1, 2].
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Laser skin resurfacing (LSR) delivers a predictable, non-
ionizing photoablative radiation that is transformed to
thermal energy on the skin surface to improve its tone,
texture, wrinkles and pigmentation [3, 4]. Apart from
reproducibility and precision, laser has the advantage over
other surface ablative measures of conforming to irregular
skin surfaces, whether convex or concave.
Several studies demonstrate that lasers disrupt the SC
outside-in barrier, disrupt the TJs inside-out barrier and
facilitate the bioavailability of molecules through the
resulting micro-channels [5, 8]. Most studies, however, rely
on in-vitro and ex vivo experiments [9]. In 2018, Badawi
and Osman [6] published one of the few reports involving
human subjects that confirmed the efficacy of laser-assisted
medication. They investigated a laser-assisted transcuta-
neous delivery of hydroquinone in the hemiface of thirty
female patients with bilateral melasma. The other hemiface
received hydroquinone only as control. The hemiface
treated with LADD exhibited a significant decrease in the
degree of pigmentation (p\ 0.005) compared to the side
treated with the hydroquinone only.
The influence of fractional ablative lasers (AFLXs) on
skin permeability accrues from some theoretical mecha-
nisms related to Fick’s first law of molecular diffusion
[7, 10]. This law states that the flux of molecules across a
membrane (e.g., the stratum corneum) is a product of the
number of molecules available for diffusion, the surface
area of the membrane and its thickness. AFLXs influence
Fick’s first law of diffusion in several ways. Firstly, these
devices reduce the thickness of the skin by removing the
SC and thus decrease the diffusion path length [10–12].
Secondly, fractional ablative lasers increase the diffusion
area by producing microthermal zones and allow the per-
meant to spread into deeper strata and penetrate laterally
toward the residual thermal damage zone [10]. The dam-
aged SC permits the penetration of molecules of high
molecular weight into deeper layers and hydrophilic drugs
to succeed in diffusing through the lipid-rich layer [3].
As the periorbital area is not flat, the laser beam colli-
mation provides regular skin penetration. Although devices
such as microneedling may be less expensive as skin
physical penetration enhancers, variables such as the dif-
ferent assembly of needles composing the devices available
in the market and the operator-dependent employment of
strength during microneedling application may cause dif-
ferent depths of penetration. Finally, the high local tem-
perature generated by the laser generates accentuated
molecular motion and consequent cutaneous permeation of
any topically applied medication toward deeper layers
[13–17]. This tissular heat explains the increased efficiency
in drug absorption using AFXLs over other physical pen-
etration enhancers [16, 17].
If there is an insufficient accumulation of a medical
substance in the stratum corneum, the permeant diffuses
into deeper strata by concentration gradient [13]. As the
drug enters the laser channels and penetrates toward the
dermis [12, 13, 18], there may be initial concerns about
systemic absorption and later risk of bacterial infection
caused by the direct exposure of underlying dermis and its
vasculature to the outside environment [17].
The immune system within skin involves a well-coor-
dinated cell-mediated and humoral immune response to
potentially harmful agents, including drugs [5, 9, 12]. This
immune response can result in cutaneous intolerance,
hypersensitivity reactions and contact dermatitis, which
can further provoke failure of transcutaneous medication
[19].
To elucidate these concerns, clinical studies in humans
are paramount because the currently available ex-vivo
studies and experimental animal models are
unsuitable [19–21].
The aim of this double-blind, prospective, randomized
clinical trial was to investigate the impact from the topical
application of different substances on skin surface imme-
diately after laser skin resurfacing and to determine if
adding growth factors to the skin surface would prove
beneficial. With this goal, two study groups were analyzed,
one control group received vitamin C, and the study group
received growth factors and vitamin C. These substances
were applied onto laser resurfaced skin wrinkles, imme-
diately after the procedure and kept under occlusion for
30 min.
The primary endpoint was the obtention of readouts
related to skin roughness (Rgh) and average depth (AD) of
facial skin wrinkles provided by a three-dimensional
stereophotogrammetry system (LifeVizTM Micro, Quan-
tificare, France). This system is linked to the software
Dermapix which quantified the change in the wrinkle’s
microtopography between baseline and 3 months after
LADD. The efficacy of each treatment regimen was sta-
tistically analyzed and compared to assess significant dif-
ferences in the skin roughness and the average depth of the
wrinkles between the two groups.
Material and Methods
The sample size calculation for this study was based on a
pilot study performed in 2017 as part of the PhD studies of
the first author. That study estimated the n of 44 patients
for each study group to have 80% power to detect the mean
difference of 0.1149 between the two related samples (SD
= 0.2635). A two-sided paired t-test was used with a sig-
nificant level of 5%. In total, 149 female patients with
Fitzpatrick skin types I–IV, aged between 43 and 70 years,
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seeking laser treatment for periorbital wrinkles were
recruited, consented and randomized into two study groups,
R-C (receiving vitamin C only) and R-CGF (receiving
vitamin C and a cosmeceutical containing growth factors).
The exposure to the chemical agents in each group was
limited to one session and only to the facial region. The
vitamin C (Vitasantisa) is approved for intravenous use
and licensed by Health Ministry, Brazil. Vitamin C has
demonstrated a beneficial effect on skin ageing [2, 22, 23],
and no toxicity has been reported when this water-soluble
vitamin was applied as part of LADD [24].
Growth factors were included in this LADD study
because there was evidence in the literature to support their
effectiveness after intravenous application as early as 1999
[26]. GFs have been rarely investigated as adjuncts to skin
rejuvenation. In theory, the artificial supplementation of
human GFs in vivo can promote skin rejuvenation
[1, 26–29] and no report of allergic reactions related to
their topical use was found in the literature. The cosme-
ceutical TNS Recovery Complex (SkinMedica, Carlsbad,
CA, USA) used in group R-CGF contained a mixture of
GFs and cytokines (VEGF, PDGF, HGF, IL-6, IL-8, and
TGF-b1) as active ingredients. The cosmeceutical was
chosen according to the Faculty Research Ethics Panel’s
request for a product approved by the CE (European
Conformity) and commercialized for topical use [25]. As
the cosmeceutical has a patented composition, we were not
able to describe the concentration of each growth factor
isolated.
Patients whose periorbital area had been treated with
botulinum toxin for up to 4 months prior to the study, or to
laser treatment, dermabrasion or chemical peeling up to
6 months before the study were excluded.
Study Design
The enrolled patients signed a consent form on the day of
treatment and were randomized into either group R-C or
R-CGF. A 3D stereophotogrammetry digital camera
(LifeVizTM Micro, Quantificare, France) was used to
photograph the relevant anatomical areas before and
3 months after the treatment. A laser tape measure was
employed to standardize the position of pre- and post-op-
erative images by using a vertical line extending from the
lateral eyebrow tail toward the jawline and horizontally
from the eyebrow tail toward the temporal hairline.
After photographic documentation, an anesthetic oint-
ment composed of lidocaine 7% and tetracaine 7% was
applied to the targeted areas for 30 min. Immediately
before the procedure, 20 mg of oral prednisolone and
10 mg of ketorolac tromethamine were given to all
patients. The eyes were protected with moist gauze and
goggles.
All patients were submitted to a single session of a
2.940 nm Erbium-Yag fractional ablative laser treatment
by the first author (Starlux 500 Palomar Inc., Burlington,
MA).
The same laser protocol was applied to all patients
(Table 1). The short pulse targeted cutaneous ablation, and
the long pulse intended tissue coagulation. The blue optics
used in this study scans with a spot size of 6 x 6 mm2 and
produces densities of 169 vertical microperforations (mi-
crobeam size: 100–140 lm) per pass, or yet, 469 microp-
erforations per cm2. Considering that 1 cm2 has
100,000,000 lm2, one laser pass with the blue optics per-
forms a total area of 56,280 lm2 of microperforations or a
density of approximately 5.6%. The separation between the
centers of each microchannel was calculated as 500 lm,
and the diameter of the microchannel opening at the skin
surface was around 100 lm.
Immediately after the laser treatment, 200 mg of vita-
min C was applied on the skin to patients in group R-C.
Patients in group R-CGF underwent topical application of
vitamin C plus the cosmeceutical containing GFs. The
treated areas of skin being investigated skin were occluded
for 30 min and protected from light exposure to avoid the
photodegradation of vitamin C. Both the researcher and the
patient were unaware of the randomized treatment given
(double-blind study).
Patients were discharged and instructed to: (1) clean the
treated area with a saline solution once a day, (2) to cover
the treated area with dexpanthenol (Bepantol–Bayer)
4 times a day until the cutaneous debris have entirely
disappeared, (3) to take Fexofenadine once a day for 5 days
and (4) not to apply cosmeceuticals and other topical
medications on the face until the follow-up visit. Valaci-
clovir prescription was restricted to patients with the pre-
vious history of herpes simplex.
Patients were monitored for adverse events. Three
months after the treatment (from January 2019 to January
2020), post-procedure photographs of the periorbital area
were taken, uploaded to the computer and transferred to the
software Dermapix. The pre- and post-procedure images
were synchronized for comparison and converted into
three-dimensional images. A contour comprising perior-
bital wrinkles was designed, and the software delivered
information on skin roughness (Rgh) and wrinkle’s average
depth (AD) before and after LADD.
Statistical Analysis
Data delivered by the software Dermapix were analyzed
by the software package SPSS IBM (Version 26.0 IBM
Corp for Mac, Armonk, New York, USA). Tests were
applied to compare and correlate skin roughness (Rgh) and
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wrinkle average depth (AD) measurements, pre- and post-
procedure.
The histograms and statistical tests for normality (Sha-
piro-Wilk and Kolmogorov-Smirnov) confirmed that the
variables had a non-Gaussian distribution in at least one
group. Data were summarized by quartiles, median, mean
and SD of the numerical variables under study. The
inferential analysis involved non-parametric-related sam-
ples tests (Wilcoxon Signed Rank Test) and independent
sample tests (Mann-Whitney U test). Spearman rho was
utilized to establish the correlation between wrinkle aver-
age depth (AD) and skin roughness (Rgh) improvement.
The criterion for determining significance was set at 5%
and the findings were considered significant with a p-value
\ 0.05.
Results
Skin crusting lasted from 5 to 8 days. Early moderate
periorbital swelling was revealed in all patients and spon-
taneously resolved by the third-day post-procedure. Post-
laser erythema appeared after the seventh day after the
procedure and subsided by the twentieth day. Hypochromia
and herpetic eruptions were not detected.
Group R-C
Of the 149 patients included in the study and randomized
according to the protocol, 74 patients were followed up in
group R-C. The age of the patients varied between 43 and
70 years old (mean 57.1 years ± 6.7 SD). The median of
AD was 0.1 mm [Interquartile Range (25th–75th per-
centile) (IQR) 0.19–0.05 mm] pre-procedure, whereas the
post-procedure measurements showed a median of 0.07
mm (IQR 0.13 to 0.03 mm). This variation is represented
in Fig. 1.
Wilcoxon Signed-Rank Test (Sig. 2-sided test) showed
that the reduction of Rgh and the AD were significant with
a p\0.01 (Table 2). Pre-procedure, the Rgh was 0.16 (IQR
01–0.22) compared to 0.13 (IQR 0.08–0.17) post-
procedure. The percentage of parameter modification (q
reduction) established the variation between the pre- and
post-measurements of a given parameter and was calcu-
lated by the mathematical formula:
q reduction (%) = (pre - post)/pre 9 100
The simultaneous computation of both parameters
(Table 2) corresponded to the sum of the q reduction of
Rgh and AD. Variables in patients submitted to LADD
with vitamin C (group R-C) showed that the Rgh presented
a median q reduction of 18.8% (IQR 7.5–29.1%) and the
AD underwent a median q reduction of 33.3% (IQR
8.5–50%). The median of the simultaneous computation of
Rgh q reduction ? AD q reduction was 50.1% (IQR
18.8–72.3%)
Figure 2 shows bi- and three-dimensional pictures of a
patient from group R-C. The delimited wrinkle exhibited
Rgh reduction by 25% (from 0.42 to 0.32) and the AD
diminished by 25% (from 0.4 to 0.3 mm). The 3D images
on the right were rotated so that graphics on the right could
show the variation of skin roughness in the area underlying
the white arrow.
Group R-CGF
From the 149 randomized participants, all 75 patients
composing group R-CGF were followed-up at 3 months.
Participants were aged from 43 to 70 years old (mean
58.05 ± 6.8 years) (Table 3).
The Wilcoxon signed-rank test confirmed that the mean
difference of the pre- and post-procedure data was signif-
icant with a p\0.01 for both variables. Pre-procedure, the
median of Rgh was 0.22 (IQR 0.15–0.34) compared to 0.11
(IQR 0.08–0.16) post-procedure. The median of AD was
0.15 mm (IQR 0.29 to 0.09 mm) pre-procedure, whereas
the post-procedure ADCGF showed a median of 0.06 (IQR
0.11– 0.02 mm) (Fig. 3).
Patients treated with LADD and topical application of
vitamin C plus the cosmeceutical containing GFs (group
R-CGF) presented median of the RghCGF q reduction by
45% (IQR 34.4–58.3%) and the median of AD q reduction
by 62.5% (IQR 34.5–81.8%). The median of the
Table 1 Fractional Erbium:Yag laser parameters protocol
Handpiece/optics Energy short pulse (250
ms)***
Energy long pulse (5
ms)
Density of microbeams (lb/
cm2)
No. of
passes
Microbeam
size
2940 nm, Blue optic
6x6 mm
9 mJ*/lb** 8 mJ/lb 469 4 120–140 lm
*mJ = milijoules (1 mJ = 0.001 Watt-sec)
**lb = microbeams (structure of optical spots through which light radiation is emitted)
***ms = miliseconds
Aesth Plast Surg
123
simultaneous computation of the Rgh q reduction ? AD q
reduction in was 105.5% (IQR 74.6–134.3%).
Figure 4 exhibits pictures of a patient submitted to
LADD with vitamin C and the cosmeceutical containing
GFs. The visual skin improvement was confirmed by the
data delivered by the 3D SPM system (on the right). Rgh
reduced by 60% (from 0.15 to 0.06) and AD diminished by
33.33% (from 0.06 to 0.04mm).
Comparison between Groups R-C and R-CGF
Spearman’s correlation coefficient (Sig 2-tailed) was used
to analyze the correlation between both variables. The
negative correlation between the Rgh and AD was signif-
icant in both groups (p\ 0.001). In group R-C, rho was
0.808 pre-procedure and became 0.780 post-procedure.
The negative correlation also became weaker in group
R-CGF, with a rho = 0.770 pre-procedure and rho = 0.680
post-procedure. This correlation represents the tendency to
Fig. 1 Boxplots representing
the reduction in skin roughness
and wrinkle average depth in
group R-C
Table 2 Descriptive analysis of the variables roughness (Rgh) and average depth (AD) in group R-C (n = 74)
Variable Group R-C (n = 74)
Pre-treatment Post-treatment Wilcoxon
signed-
rank
test
Mean/SD Median IQR (25th–
75th
percentiles)
Min Max Mean/SD Post
median
IQR (25th
75th
percentiles)
Min Max p-value
Age
(years)
57.1 ± 6.7 57 52.0–62.3 43 70 57.1 ± 6.7 57 52.0–62.3 43 70 n/a
Rgh 0.17 ± 0.09 0.16 0.10–0.22 0.03 0.44 0.14 ± 0.08 0.13 0.08–0.17 0.03 0.41 \ 0.01
AD - 0.13 ±
0.09
- 0.11 - 0.19 to
- 0.05
- 0.4 - 0.01 - 0.09 ±
0.07
- 0.07 - 0.13 to
- 0.03
- 0.30 - 0.01 \ 0.01
Rgh q reduction (%) 15.5 18.8 7.5–29.1 - 27.3 59.5 n/a
AD q reduction (%) 30.5 ± 30.7 33.3 8.5–50.0 - 66.7 83.3 n/a
Simultaneous computation of AD and Rgh q reduction (%) 49.5 ± 35.7 50.1 18.8–72.3 - 31.3 132 n/a
IQR Interquartile Range (25th–75th percentile)
Min Minimum; Max Maximum; n/a not applicable
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skin flattening and suggests that LADD was able to inter-
fere with both variables at the same time.
According to the Mann-Whitney test (Table 4), the q
reduction of AD, Rgh and the simultaneous reduction in
both parameters were significantly higher in group R-CGF
(p\0.01). These findings confirmed that patients submitted
to LADD, using vitamin C and GFs blended into a cos-
meceutical, produced statistically significant better results
than those treated with LADD followed by vitamin C
alone.
No bias resulted from gender variation or age hetero-
geneity because all patients were females, and the age
variation between both groups was not significant (p =
0.39).
The concealment of protuberant vessels involving the
application of GFs was confirmed as a secondary outcome
by the statistical analysis and the clinical examination.
Figure 5 shows one patient from group R-C who presented
conspicuous periorbital veins. The skin improvement
occurred but was not sufficient to conceal those vessels. On
the other hand, Fig. 6 presents a patient from group R-CGF
in which the roughness of the area comprising the promi-
nent temporal superficial veins reduced from 0.35 to 0.1,
which corresponded to Rgh q reduction of 71.4%. The
wrinkle selected for analysis showed a simultaneous
reduction of AD and Rgh 90%. As the prominent vessels
cause elevations in an area that usually presents a regular
surface and discrete demotions, the enhancement of the
skin thickness has permitted for the correction of the
undesired elevation and the return of the skin cover to a
slight natural depression. That is the reason for the
Fig. 2 A 69-year-old patient from group R-C. The post-procedure
images were obtained the 94th day. The software permitted the
rotation of the images, and this provided a different perspective and
visualization of the periorbital skin roughness modification. The
graphs on the right correspond to the skin roughness under the
designed arrow
Aesth Plast Surg
123
Table 3 Descriptive analysis of the variables roughness (Rgh) and average depth (AD) in group R-CGF (n = 75)
Group R-CGF (n = 75)
Pre-treatment Post-treatment Wilcoxon
rank test
Variable Mean/
Sd
Median IQR (25th–
75th
percentiles)
Min max Mean/SD Median IQR (25th–
75th
percentiles)
Min Max p-value
Age (years) 58.05
±
6.8
57.0 53.0 to
63.0
43.0 70.0 58.05 ± 6.8 57.0 53.0 to
63.0
43.0 70.0 n/a
Rgh 0.26
±
0.18
0.22 0.15 to
0.34
0.06 1.31 0.13 ± 0.1 0.11 0.08 to
0.16
0.04 0.61 \ 0.01
AD 0.19
±
0.14
0.15 - 0.29 to
- 0.09
- 0.56 - 0.01 - 0.08 ± 0.08 0.06 - 0.11 to
- 0.02
- 0.41 - 0.01 \ 0.01
Rgh q reduction
(%)
n/a n/a n/a n/a n/a 45.8 ± 17.4 45.0 34.4 to
58.3
4.7 79.0 n/a
AD q reduction
(%)
n/a n/a n/a n/a n/a 57.2 ± 27.3 62.5 34.5 to
81.8
- 2.6 95.8 n/a
Simultaneous
computation of
AD and Rgh q
reduction (%)
n/a n/a n/a n/a n/a 103 ± 37.4 105.5 74.6 to
134.3
2.1 165 n/a
IQR interquartile range (25th–75th percentile)
Min Minimum; Max Maximum; n/a not applicable
Fig. 3 Boxplots representing the modification of skin roughness and wrinkle average depth of group R-CGF
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increased average depth in the post-treatment photograph
in Fig. 6.
Discussion
Facial rejuvenation surgical procedures naturally provide
more impressive visual benefits to the patients as they
remove skin in the scale of centimeters. However,
Fig. 4 The pictures of a 57-year-old patient from group R-CGF. Pictures were obtained on the 90th day post-procedure. The software permitted
the rotation of the images and graphics that illustrated the variation in the skin roughness pre- and post-procedure
Table 4 Descriptive analysis of the variables (roughness and average depth) according to the two treatment regimens–Mann-Whitney test
Variable Group C (n = 74) Group CGF (n = 75) p-value
Median IQI Median IQI
Age (years) 57.1 52.0 to 62.3 58.1 53.0 to 63.0 0.39
Rgh pre-procedure 0.16 0.10 to 0.22 0.22 0.15 to 0.34 \0.01
Rgh post-procedure 0.13 0.08 to 0.17 0.11 0.08 to 0.16 0.50
Rgh q reduction (%) 18.8 7.5 to 29.1 45.0 34.4 to 58.3 \ 0.001
AD pre-procedure - 0.11 - 0.19 to - 0.05 - 0.15 - 0.29 to - 0.09 = 0.001
AD post-procedure - 0.07 - 0.13 to - 0.03 - 0.06 - 0.11 to - 0.02 0.27
AD q reduction (%) 33.3 8.5 to 50.0 62.5 34.5 to 81.8 \ 0.001
Simultaneous computation of AD and Rgh q reduction (%) 50.1 18.8 to 72.3 105.5 74.6 to 134.3 \ 0.001
IQI interquartile interval (Q1–Q3); Mann-Whitney test
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addressing the skin cover on facial areas has become an
important ancillary procedure, especially when the sun
exposure, or other extrinsic or intrinsic factors have led the
skin to present alterations in its microstructure in the form
of mottled pigmentation and wrinkles.
The development of fractional ablative lasers (AFLXs)
has permitted for safe and effective skin rejuvenation.
AFXLs produce partial ablation of the SC and microper-
forations into the dermis that can potentially be used as a
physical penetration enhancer to treat several skin condi-
tions. Although the use of lasers is not compulsory to
improve skin quality and is expensive, when a well-
established protocol is used, the precision of the laser
computerized system eliminates potential technique-de-
pendent bias regarding the depth of skin microperforation.
The percentage of skin treated with AFXLs and subse-
quent tissue reaction are dictated by the energy output,
density setting, the number of times that the laser hits the
target tissue (pulse repetition) and the pulse duration
[8, 11, 23]. The density is the number of (microthermal
thermal zones) MTZs produced by the laser per unit area
(cm2), and it varies with the number of laser passes. The
Fig. 5 The bi- and three-dimensional pictures of a 68-year-old patient submitted to LADD with vitamin C. Data on the right were collected by
the 3D SPM at the 90th day post-procedure and concern the relief of the periorbital vein
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lasers settings also influence laser-tissue-drug interaction
and consequent drug delivery and bio-distribution
[11, 17, 30].
The concentrations of the product in skin aiming at
laser-assisted medication or laser-assisted drug delivery are
reported to stabilize when densities up to 5% are reached
[16, 17, 31]. In 2014, Sklar et al. found that the application
of low densities facilitates optimal intracutaneous drug
accumulation and that the use of higher densities led to
significant reductions in both intra- and transcutaneous
delivery per single MTZ [8]. However, that was an ex vivo
study, and this type of investigation neglects the dermal
dynamic blood flow, which may be responsible for the
absence of drug saturation in vivo.
The laser protocol utilized in this study proved efficient
in providing drug penetration of macromolecules (GFs and
cytokines). We have restricted the number of passes over
the same skin surface area to 4 times because the target
chromophore (water) reduces after each pass. Several laser
passages over the tissue increase the risk of thermal injury
and neither enhance the drug uptake nor the effectiveness
of the treatment [8, 23, 32].
According to the literature, another factor that can
impact the result of the treatment is the time lag before
applying the medication, because the spatiotemporal clo-
sure of AFXL-induced channels occurs within 24–48 hours
after laser exposure. The dermis can quickly become
inaccessible owing to the deposition of debris, fibrin,
inflammatory mediators and keratinocytes inside the
microchannels [16]. Both study groups underwent tran-
scutaneous medication during the first 30 min post-proce-
dure, after gentle skin cleaning. This thirty-minute period
Fig. 6 Pictures of a 66-year-old patient submitted to LADD with vitamin C and the blend of GFs. The post-procedure images were obtained on
the 93th day. The prominent temporal superficial veins became less visible after the treatment
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was recently confirmed as the optimal interval for LADD
[15]. Nonetheless, any residual disruption of cutaneous
layers can still be observed 3 weeks after LSR [4, 10, 11].
This time-lapse must be evaluated in future studies to
establish the therapeutic window for the topical delivery of
medication.
Despite the promising results, previous clinical studies
have emphasized the theoretical risk of induced systemic
toxicity [11, 33]. This highlights questions linked to reg-
ulatory approval and has limited further objective research
and restricted the commercialization of active delivery
products [20, 34]. It is difficult, if not impossible, to
determine cutaneous drug penetration based solely on
molecular properties when there are other confounding
factors such as dietary intake, endogenous production of
substances, variable blood flow and the complex, new
surface area and geometry created by the laser-induced
microchannels. Therefore, clinical trials are essential to
determine the safety of this therapeutic modality. To date,
no adverse toxicity has ever actually been linked to LADD
[7, 16, 26, 35].
The pharmacological supplementation of GFs is
described to exert a therapeutic benefit to scarring and skin
senescence because the artificial is supposed to mimic the
physiological, molecular biology process to promote skin
rejuvenation and enhance the self-healing capacity
[1, 26–29]. However, investigation on human subjects are
scarce, and some studies involved a low number of
patients, which reinforces the importance of this clinical
study. In 2006, Erlich et al. published a blinded compara-
tive study on 12 healthy females with facial wrinkles (mean
50 years-old) [26]. The patients elected one hemiface to
apply a cosmeceutical containing transforming growth
factor beta 1 (TGF-b1), L-ascorbic acid, and Cimicifuga
racemosa extract and the other side received the cosme-
ceutical used in the present clinical study. Both products
provided significant improvement in facial rhytids, but the
authors suggested that the supplementation of L-ascorbic
acid (vitamin C) was essential in proportioning skin
improvement [26].
After thermal and physical trauma such as laser skin
resurfacing, the fibroblasts replace the initial ECM under
the influence of GFs, producing type III collagen and
adult/mature type I collagen in the scar. Type IV collagen
is produced at the dermal-epidermal junction. GFs bind to
their specific receptors on the cell surface and this inter-
action activates several molecular events that are essential
for wound healing and tissue repair [1, 24]. The major GF
families involved in these processes are the epidermal
growth factor (EGF), keratinocyte growth factor (KGF),
fibroblast growth factor (FGF), platelet-derived growth
factor (PDGF), TGF-bs (transforming growth factor beta),
heparin-binding growth factor (HGF) and vascular
endothelial growth factor (VEGF). These GF families
(i) regulate the growth, differentiation, proliferation and
cellular influx of fibroblasts and monocytes, (ii) affect
collagen and ECM biosynthesis and (iii) promote neoan-
giogenesis [1, 4].
GFs poorly penetrate the skin because they are hydro-
philic proteins composed of hundreds of amino acids with
molecular size larger than 15000 Da [1]. Another restric-
tion to using GFs within any transcutaneous medication is
related to their low stability [36, 37]. The effectiveness of
GFs is quickly nullified due to clearance from the site by
diffusion, or inactivation by proteolytic cleavage. If the
degradation is excessive, the biomolecules may not exist at
sufficient concentrations to exert their functions. As the
mode of delivery of GFs may interfere with the therapeutic
success [37], this study confirms that the incorporation of
GFs as part of LADD can be efficient and does not require
supraphysiologic doses of GFs to ensure a sufficient active
concentration. For ethical reasons, it was not possible to
use GFs as part of a composition with known concentra-
tions and obliged the use of a blend of GFs contained in a
patented formula.
Based on the already established knowledge that the
lasers influence drug delivery and consequent bio-distri-
bution [11, 17, 30], the objective of this study was to
determine if the addition of growth factors to the skin
immediately after laser skin resurfacing would impact the
result of the treatment. As the effect of LSR in skin reju-
venation has already been demonstrated, there was no need
to investigate the effect of laser alone [3, 11, 22]. There-
fore, the group receiving vitamin C only was established as
the control group. The group receiving two medications
(vitamin C and the cosmeceuticals containing GFs) pre-
sented statistically significant better results than the control
group, which was medicated with vitamin C only.
Although it is not possible to establish to what extent the
by-pass of the epidermal layers protects the GFs from
degradation, this is an important finding because high
concentrations of compounds restrict regulatory approval
of medications and cause the medication to be very costly.
In addition, the treatment has been well-tolerated as the
149 patients treated in the present study did not present any
adverse reaction due to topical application of medications.
Conclusion
Laser skin resurfacing is a therapeutic modality that can
deliver thermal energy to a skin surface to reduce wrinkles,
and improve skin tone, texture and pigmentation. The
collimation of the laser light on the surface of skin pro-
duces micro-channels into the dermis at a homogeneous
depth, irrespective the irregularity of the wrinkles. AFXLs
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can facilitate the bioavailability of molecules through the
resultant micro-channels. By interrupting the integrity of
the SC, lasers reduce the diffusional path length (mem-
brane thickness) and the superficially applied drug fills the
laser channels and penetrates into the dermis.
As the skin is a structure that is subjected to alterations
under the scale of micrometers, the results of laser skin
resurfacing (LSR) may seem less expressive than surgical
procedures aiming at skin rejuvenation. However, this
study reinforces the potential of using LADD as an ancil-
lary procedure to enhance facial treatment results. The
statistical analysis demonstrates an improvement in peri-
orbital wrinkles in both treatment groups, but the addition
of a cosmeceutical containing GFs provided significantly
better results. This finding indicates that intradermal direct
delivery of GFs, by-passing the epidermis, may protect the
GFs from enzymatic action and permit a direct bioactive
effect. LADD with vitamin C and GFs has proven to be
safe and effective, and there were no unexpected local
tissue reactions or adverse systemic reactions to either of
the LADD substances being investigated.
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